Related Experiment Video
Updated: May 1, 2026
Intrastriatal Injection of Autologous Blood or Clostridial Collagenase as Murine Models of Intracerebral Hemorrhage
Published on: July 3, 2014
Necrostatin-1 reduces neurovascular injury after intracerebral hemorrhage
Melanie D King1, Wittstatt A Whitaker-Lea1, James M Campbell1
1Department of Neurosurgery, Medical College of Georgia, Georgia Regents University, 1120 15th Street, Augusta, GA 30912, USA.
Insights
Necrostatin-1 significantly reduced brain damage and improved outcomes in a mouse model of intracerebral hemorrhage (ICH). This necroptosis inhibitor shows promise for treating hemorrhagic stroke.
Area of Science:
- Neuroscience
- Stroke Research
- Cell Death Mechanisms
Background:
- Intracerebral hemorrhage (ICH) is a severe stroke type with high mortality and limited treatment options.
- Novel therapeutic targets are urgently needed for ICH.
- Previous research indicated necrostatin-1 may protect against neurovascular injury in vitro.
Purpose of the Study:
- To investigate the efficacy of necrostatin-1 in reducing neurovascular injury in a mouse model of ICH.
- To test the hypothesis that necrostatin-1 mitigates damage following collagenase-induced ICH.
Main Methods:
- Collagenase-induced ICH model in mice.
- Administration of necrostatin-1 or an inactive analogue.
- Assessment of hematoma volume, cell death, blood-brain barrier integrity, edema, and neurobehavioral outcomes at 72 hours post-ICH.
Main Results:
- Necrostatin-1 reduced hematoma volume by 54%.
- Necrostatin-1 decreased cell death by 48% and blood-brain barrier opening by 51%.
- Edema was attenuated, and neurobehavioral outcomes improved in necrostatin-1 treated mice.
Conclusions:
- Necrostatin-1 demonstrates significant neuroprotective effects in a mouse model of ICH.
- Necrostatin-1 reduces key pathological markers of ICH and improves functional recovery.
- These findings suggest necrostatin-1 or related necroptosis inhibitors could be valuable adjunct therapies for ICH.
Abstract:
Intracerebral hemorrhage (ICH) is the most common form of hemorrhagic stroke, accounting for 15% of all strokes. ICH has the highest acute mortality and the worst long-term prognosis of all stroke subtypes. Unfortunately, the dearth of clinically effective treatment options makes ICH the least treatable form of stroke, emphasizing the need for novel therapeutic targets. Recent work by our laboratory identified a novel role for the necroptosis inhibitor, necrostatin-1, in limiting neurovascular injury in tissue culture models of hemorrhagic injury. In the present study, we tested the hypothesis that necrostatin-1 reduces neurovascular injury after collagenase-induced ICH in mice. Necrostatin-1 significantly reduced hematoma volume by 54% at 72 h after-ICH, as compared to either sham-injured mice or mice administered an inactive, structural analogue of necrostatin-1. Necrostatin-1 also limited cell death by 48%, reduced blood-brain barrier opening by 51%, attenuated edema development to sham levels, and improved neurobehavioral outcomes after ICH. These data suggest a potential clinical utility for necrostatin-1 and/or novel necroptosis inhibitors as an adjunct therapy to reduce neurological injury and improve patient outcomes after ICH.
